Evidence map›Paper›PMID 38546223›Full record

ArticleAntimicrobial agents and chemotherapy2024

Population-specific variations in

Mahamadou D Camara, Yitian Zhou, Antoine Dara, Mamadou M Tékété, Taís Nóbrega de Sousa, Sékou Sissoko, Laurent Dembélé, Nouhoun Ouologuem, Amadou Hamidou Togo, Mohamed L Alhousseini and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 5 countries.

Mahamadou D CamaraDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Yitian ZhouDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-3066-5444
Antoine DaraDepartment of Epidemiology of Parasitic Diseases, Malaria Research and Training Center, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali.
Mamadou M TékétéDepartment of Epidemiology of Parasitic Diseases, Malaria Research and Training Center, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali.
Taís Nóbrega de SousaDepartment of Microbiology and Tumour Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Sékou SissokoDepartment of Epidemiology of Parasitic Diseases, Malaria Research and Training Center, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali.
Laurent DembéléDepartment of Epidemiology of Parasitic Diseases, Malaria Research and Training Center, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali.ORCID 0000-0001-9087-8439
Nouhoun OuologuemDepartment of Epidemiology of Parasitic Diseases, Malaria Research and Training Center, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali.
Amadou Hamidou TogoDepartment of Epidemiology of Parasitic Diseases, Malaria Research and Training Center, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali.
Mohamed L AlhousseiniDepartment of Epidemiology of Parasitic Diseases, Malaria Research and Training Center, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali.
Bakary FofanaDepartment of Epidemiology of Parasitic Diseases, Malaria Research and Training Center, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali.
Issaka SagaraDepartment of Epidemiology of Parasitic Diseases, Malaria Research and Training Center, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali.
Abdoulaye A DjimdeDepartment of Epidemiology of Parasitic Diseases, Malaria Research and Training Center, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali.
Pedro J GilDepartment of Microbiology and Tumour Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Volker M LauschkeDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-1140-6204
University of Bamako · MLKarolinska Institutet · SEUniversity of Lisbon · PT

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 200075/2022-5EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership (EDCTP) RIA2017T-2018Vetenskapsrådet (VR) 2019-01837, 2021-02801, 2021-05666, 2021-06048
6 · The paper itself

Abstract

Dihydroartemisinin-piperaquine is efficacious for the treatment of uncomplicated malaria and its use is increasing globally. Despite the positive results in fighting malaria, inhibition of the Kv11.1 channel (hERG; encoded by the

Indexed as

AntimalarialsArtemisininsERG1 Potassium ChannelPiperazinesQuinolinesAdultElectrocardiographyFemaleHumansLong QT SyndromeMalariaMalePolymorphism, Single NucleotideAntimalarialsArtemisininsartenimolERG1 Potassium ChannelKCNH2 protein, humanpiperaquinePiperazinesQuinolinescardiotoxicityhERGKv11.1long QTmalariaQT prolongation

Identifiers

PMID38546223
PMCPMC11064487
OpenAlexW4393259747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.